|
Sorted by: Date | Top Results
|
|
Author |
|
Date |
| |
| |
| 1. |
Re: nibble nibble .... had to at 5.16 
me too at 5.20
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
28-Jan-10 01:59 pm |
| |
| 2. |
I&&39;m still way ahead
ok, so I'm down $4k-$5k. I still cash in over $20k
last Jan. I'm the one who sold afterhours between
$11.75- $12.00/share
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
20-Jan-10 02:04 pm |
| |
| 3. |
Re: Approved in Europe for 12+ years.
They know that if 7% of the study participants got
high blood pressure during the study while taking
a placebo then thats considered as a base of what
could be...
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
20-Jan-10 01:39 pm |
| |
| 4. |
Re: Approved in Europe for 12+ years.
yes, even 7% of the sick people taking the placebo
got high blood pressure during the study. That amount
are then understood to get high blood pressure even
without the drug. Sometimes sick people get...
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
20-Jan-10 01:03 pm |
| |
| 5. |
FDA
Drug is safe and doctors warned about need for constant
blood pressure monitoring. Pre-approval studies were
also reformulated by DIRECTION of the FDA to...
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
20-Jan-10 12:56 pm |
| |
| 6. |
Re: Approved in Europe for 12+ years.
it's called cause and effect. some people are going
to develop high blood pressure anyway during a test
regardless of the drug tested. that's why patients
taking...
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
20-Jan-10 12:51 pm |
| |
| 7. |
Re: Approved in Europe for 12+ years.
I agree. Drug is safe and doctors warned about need
for constant blood pressure monitoring. Pre-approval
studies were also reformulated by DIRECTION of th
e...
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
20-Jan-10 12:33 pm |
| |
| 8. |
Re: Blackrock
Of course I knew. The day Savella was approved - ""Savella
is expected in pharmacies by March. Common side effects
reported during clinical...
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
20-Jan-10 12:22 pm |
| |
| 9. |
multi-hundred million dollar potential
Forest’s most recent product launch, Savella, which
is approved for the management of fibromyalgia, posted
sales of $15.4 million. The product, which has be
en...
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
19-Jan-10 05:31 pm |
| |
| 10. |
Add now
and because of what I know now from Forest's conference
call if they're crazy enough to test the $5.75
level again I'd probably add another 2,000 th
ere.
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
19-Jan-10 02:30 pm |
| |
| 11. |
Re: CYPB Buyout if Bought for 3 x Revenue
"Anyone inclined to add might want to wait for
cypb's report in the coming days as they usually
use 'higher expenses' and uncertain cash deployment
as reasons...
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
19-Jan-10 02:25 pm |
| |
| 12. |
Re: Finally, some script numbers from FRX
"Is $10/share high of low? Well, it equates to
6 x the annualized end of 2010 cost to Forest. Of
course, the revenues would likely keep growing, perhaps
10...
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
19-Jan-10 12:50 pm |
| |
| 13. |
Re: Finally, some script numbers from FRX
a current assessment of buyout value for 2010 $60M
annual rate of Savella sales for last qtr, Forest
just said Savella has a 6.3% mkt sh with wk/wk prescriptions
rising 3...
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
19-Jan-10 11:26 am |
| |
| 14. |
Sales increase 1500 times QTR over QTR
$15.4 million savella sales for the qtr, that's
$61 million annual rate and increase 150,000% = 1500
times from full second quarter sales of $10,270
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
19-Jan-10 08:39 am |
| |
| 15. |
Sales increase 1500 Times QTR over QTR
$15.4 million savella sales for the qtr, that's
$61 million annual rate and increase 150,000% = 1500
times from full second quarter sales of $10,270
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
19-Jan-10 08:37 am |
| |
| 16. |
Re: savella approved 1 year ago
and as my first post shows market just reevaluted the
value of Savella to cypb today.
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
15-Jan-10 11:56 am |
| |
| 17. |
Re: savella approved 1 year ago
sometimes simplicity is best when trying to deflate
unjustifiable correlations, such as is implied that
Kranzler was somehow responsible for the $2 decline
from a year ago. I...
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
15-Jan-10 11:52 am |
| |
| 18. |
Re: savella approved 1 year ago
if Kranzler did such a poor job in moving the price
down $2 from a year ago, What did he do RIGHT when
the price increased $3 from May to July. Sometimes
stocks go up because of what CEO's...
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
15-Jan-10 10:25 am |
| |
| 19. |
higher estimates higher ranking
zack's just raised cypb rank from a 3 (average)
(hold) to a 2 (buy) Macquarie Capital Securities raises
earnings est for qtr's and yr Zacks Investment
Research raises earnings est for qtr's and yr
...
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
15-Jan-10 09:25 am |
| |
| 20. |
Re: Scripts anyone?
next good info next week from forest's report and
conf call
Business & Finance > Investments > Stocks (A to Z) > Stocks C >
Cypress Bioscience, Inc.
|
|
goldstrawsteven |
|
13-Jan-10 02:54 pm |
| |